Comparison of MSCs and Muse cells: the possible use for healthspan optimization.

In approximately 80% of patients, scores on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) remained stable for up to 10 months after initiating cell administration, whereas about 20% showed a trend toward deterioration—findings that strongly support the therapeutic potential of donor Muse cell treatment mitigating ALS symptom progression (Yamashita et al. 2023 ).

also in 53,322 other papers